A Phase 3 interventional study of Amlodipine and hydrochlorothiazide in Hypertension, sponsored by Novartis. Completed at 10 sites in 10 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2011-10-17.
Sponsored by Novartis · Phase 3, Interventional, and Diagnostic
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 187 studies testing amlodipine in Hypertension — 6 open to participants now, 8 under way, 2 of them phase 3. Amlodipine · Hypertension.
Among the 187 studies testing amlodipine in Hypertension, this one is the 17th largest by enrollment of the 186 interventional ones that give a count, is one of 14 that started in 2008, is one of 69 in phase 3, and was the 70th registered.
6,128 studies on the registry are indexed under Hypertension; 911 are open to participants now.
Browse Hypertension studies →6 of the 187 studies testing amlodipine in Hypertension are open now, in 4 countries. Recruiting first, the newest first:
National Medical Research Center for Therapy and Preventive Medicine · Sites in Russia
Ages 50–70
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Shenzhen Ausa Pharmed Co.,Ltd · Sites in China
Ages 45–74
Hyundai Pharm · Sites in Korea, Republic of
Ages 19+
Zentiva, k.s.
Ages 50–79 · Women only
By country, each count listing its studies:
Amlodipine: first FDA approval 1992 (NORVASC), first EMA approval 2007. What it is approved for, and how studies give it, is on its page →
Of the 556 Hypertension studies recruiting now, 262 (47%) set no upper age limit and 198 (36%) stop at 75 or younger; 40 take children under 18; 137 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
187 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 17 · Phase 2 9 · Phase 3 71 · Phase 4 80
First in 1999; this study’s year is marked. 14 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,254 is above the median of 100 across 4,585 interventional studies indexed under Hypertension.
Median enrollment 180 across the 186 interventional studies. Of the 156 that completed or were terminated, 53 (34%) have results posted.
This tab as a report to print or save as PDF → With an account.
120 of 187 have an industry lead sponsor. The 10 most frequent:
Novartis is the lead sponsor of 714 studies on the registry; none are open to participants now.
228 studies in Hypertension by Novartis: 5 open now, 6 under way, none of them phase 3. Of 219 finished, 88 (40%) have results posted.
Among the 228 studies in Hypertension by Novartis, this one is the 20th largest by enrollment of the 223 interventional ones that give a count, is one of 25 that started in 2008, is one of 108 in phase 3, and was the 150th registered.
Novartis’s Hypertension studies by the year they started, since 1989.
None of the studies under way reaches primary completion within a year.
Among the 187 studies testing amlodipine in Hypertension, from their registry updates:
Among Novartis’s 228 in Hypertension:
This tab as a report to print or save as PDF → With an account.
This study will compare the safety and efficacy of initial combination treatment with aliskiren + amlodipine to sequential add-on treatment strategies with aliskiren or amlodipine in patients with hypertension.
This study was designed to evaluate if patients with hypertension treated early with a combination therapy would achieve better blood pressure (BP) control, than patients being treated with a classical sequential add-on therapy.
The study compared the effects of the two treatment strategies: Treatment initiation on a single compound, either with aliskiren or amlodipine, and then continuation with the combination of both versus treatment initiation with the combination of aliskiren/amlodipine and then continuation with the combination. The study also evaluated if the overall mean sitting systolic blood pressure (msSBP)-lowering effect during the study, as well as the change from baseline to study end in msSBP, are superior in the group having received combination therapy from the beginning.
The study further evaluated the BP-lowering efficacy and tolerability of both treatment strategies.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Participants with essential hypertension:
Exclusion Criteria:
Other protocol-defined inclusion/exclusion criteria may apply.
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Eligible participants received oral aliskiren 150 mg + amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of the combination treatment increased to aliskiren 300 mg + amlodipine 10 mg daily. From week 16-24, participants in this group continued combination treatment (aliskiren 300 mg + amlodipine 10 mg) for 8 weeks. At week 24, if blood pressure was not adequately controlled (systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
Drug: Amlodipine · Drug: hydrochlorothiazide · Drug: Aliskiren
Eligible participants received oral aliskiren 150 mg daily from week 1-8. From week 8 - 16, the dose of aliskiren increased to 300 mg daily. From week 16-24, amlodipine 10 mg was added to the aliskiren 300 mg for 8 weeks (aliskiren 300 mg + amlodipine 10 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (aliskiren 300 mg + amlodipine 10 mg) for an additional 8 weeks. Total treatment period =32 weeks.
Drug: Amlodipine · Drug: hydrochlorothiazide · Drug: Aliskiren
Eligible participants received oral amlodipine 5 mg daily from week 1-8. From week 8 - 16, the dose of amlodipine increased to 10 mg daily. From week 16-24, aliskiren 300 mg was added to the amlodipine 10 mg for 8 weeks (amlodipine 10 mg + aliskiren 300 mg). At week 24, if blood pressure was not adequately controlled (systolic blood pressure \>140 mmHg or diastolic blood pressure \>90 mmHg) hydrochlorothiazide 12.5 mg was added to the combination (amlodipine 10 mg + aliskiren 300 mg) for an additional 8 weeks. Total treatment period =32 weeks.
Drug: Amlodipine · Drug: hydrochlorothiazide · Drug: Aliskiren
Amlodipine (5 mg and 10 mg) was provided as capsules taken orally once daily.
Also known as: Norvasc
Hydrochlorothiazide 12.5 mg capsules were taken orally once daily
Also known as: Esidrix, HydroDIURIL, Oretic, Ezide, Hydro-Par
Aliskiren 150 mg and aliskiren 300 mg were provided as film-coated tablets, taken orally once daily.
Also known as: SPA 100
Overall Mean Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Over 8, 16 and 24 Weeks
Systolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msSBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures Analysis of Covariance (ANCOVA) model with treatment, visit, and region as factors, treatment by visit interaction and baseline msSBP as a covariate.
Time frame: Baseline, 8 weeks, 16 weeks, and 24 weeks
Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 24
Systolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region as factors, treatment by visit interaction and baseline msSBP as a covariate.
Time frame: Baseline to 24 weeks
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 32
Diastolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 32 weeks of study treatment. Change at Week 32 used a separate repeated measures ANCOVA model containing Week 8, 16, 24 and 32 data. Treatment, visit and region were factors in the model, treatment by visit interaction and baseline msDBP a covariate.
Time frame: Baseline to 32 weeks
Overall Mean Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Over 8, 16, and 24 Weeks
Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msDBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures ANCOVA model with treatment, visit and regions as factors, treatment by visit interaction and baseline msDBP as a covariate.
Time frame: Baseline, 8 weeks, 16 weeks and 24 weeks
Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 24
Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region, as factors, treatment by visit interaction and baseline msDBP as a covariate.
Time frame: Baseline to 24 weeks
Percentage of Participants Achieving Overall Blood Pressure Control at 8, 16, 24 and 32 Weeks Endpoints
Systolic \& Diastolic Blood Pressure were measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and after 8, 16 , 24 and 32 weeks. Outcome is reported as percentage of participants achieving overall blood pressure control (msSBP \<140 mmHg and msDBP \<90 mmHg) at weeks 8, 16, 24 \& 32 endpoints.
Time frame: Baseline to week 8, 16, 24 and 32 endpoints
| Milestone | Aliskiren+Amlodipine | Aliskiren Start-Amlodipine Add On | Amlodipine Start-Aliskiren Add On |
|---|---|---|---|
| Started | 620 | 318 | 316 |
| Entered double-blind treatment (fas) | 617 | 315 | 315 |
| Completed | 496 | 250 | 230 |
| Not completed | 124 | 68 | 86 |
| Withdrew: Adverse event | 86 | 44 | 58 |
| Withdrew: Abnormal test procedure result | 0 | 1 | 1 |
| Withdrew: Lack of efficacy | 1 | 7 | 6 |
| Withdrew: No longer required study medication | 1 | 0 | 0 |
| Withdrew: Withdrawal by subject | 14 | 7 | 7 |
| Withdrew: Lost to follow-up | 11 | 0 | 5 |
| Withdrew: Administrative problem | 4 | 0 | 0 |
| Withdrew: Protocol violation | 4 | 6 | 8 |
| Withdrew: Mis-randomized | 3 | 3 | 1 |
Systolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msSBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures Analysis of Covariance (ANCOVA) model with treatment, visit, and region as factors, treatment by visit interaction and baseline msSBP as a covariate.
| mmHg | Aliskiren+Amlodipine | Aliskiren Start-Amlodipine Add On | Amlodipine Start-Aliskiren Add On |
|---|---|---|---|
| Overall Mean Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) Over 8, 16 and 24 Weeks | -25.34 ± 0.436 | -17.94 ± 0.600 | -19.81 ± 0.611 |
Systolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region as factors, treatment by visit interaction and baseline msSBP as a covariate.
| mmHg | Aliskiren+Amlodipine | Aliskiren Start-Amlodipine Add On | Amlodipine Start-Aliskiren Add On |
|---|---|---|---|
| Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 24 | -27.37 ± 0.546 | -26.34 ± 0.738 | -25.52 ± 0.782 |
Diastolic Blood Pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 32 weeks of study treatment. Change at Week 32 used a separate repeated measures ANCOVA model containing Week 8, 16, 24 and 32 data. Treatment, visit and region were factors in the model, treatment by visit interaction and baseline msDBP a covariate.
| mmHg | Aliskiren+Amlodipine | Aliskiren Start-Amlodipine Add On | Amlodipine Start-Aliskiren Add On |
|---|---|---|---|
| Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 32 | -12.96 ± 0.323 | -12.96 ± 0.446 | -11.62 ± 0.467 |
Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and over 8, 16 and 24 weeks of study treatment. The overall mean change in msDBP from baseline was estimated over three time points: Week 8, Week 16, and Week 24. Analysis used a repeated measures ANCOVA model with treatment, visit and regions as factors, treatment by visit interaction and baseline msDBP as a covariate.
| mmHg | Aliskiren+Amlodipine | Aliskiren Start-Amlodipine Add On | Amlodipine Start-Aliskiren Add On |
|---|---|---|---|
| Overall Mean Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) Over 8, 16, and 24 Weeks | -12.39 ± 0.247 | -8.37 ± 0.340 | -9.02 ± 0.347 |
Diastolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 24 weeks of study treatment. Analysis used a repeated measures ANCOVA model with treatment, visit and region, as factors, treatment by visit interaction and baseline msDBP as a covariate.
| mmHg | Aliskiren+Amlodipine | Aliskiren Start-Amlodipine Add On | Amlodipine Start-Aliskiren Add On |
|---|---|---|---|
| Change From Baseline in Mean Sitting Diastolic Blood Pressure (msDBP) at Week 24 | -13.64 ± 0.319 | -13.22 ± 0.431 | -12.25 ± 0.457 |
Systolic \& Diastolic Blood Pressure were measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and after 8, 16 , 24 and 32 weeks. Outcome is reported as percentage of participants achieving overall blood pressure control (msSBP \<140 mmHg and msDBP \<90 mmHg) at weeks 8, 16, 24 \& 32 endpoints.
| Percentage of Participants | Aliskiren+Amlodipine | Aliskiren Start-Amlodipine Add On | Amlodipine Start-Aliskiren Add On |
|---|---|---|---|
| Week 8 endpoint | 46.5 ± 0.566 | 22.8 ± 0.781 | 25.2 ± 0.816 |
| Week 16 endpoint | 65.9 | 33.3 | 40.9 |
| Week 24 endpoint | 63.4 | 62.8 | 57.8 |
| Week 32 endpoint | 61.6 | 59.0 | 53.4 |
Systolic Blood pressure was measured in a sitting position using a validated automated blood pressure monitor (the Omron device) according to Guidelines of the British Hypertension Society, at Baseline and 32 weeks of study treatment. Change at week 32 used a separate repeated measures ANCOVA model containing Week 8, 16, 24 \& 32 data. Treatment, visit and region were factors in the model, treatment by visit interaction and baseline msSBP was a covariate.
| mmHg | Aliskiren+Amlodipine | Aliskiren Start-Amlodipine Add On | Amlodipine Start-Aliskiren Add On |
|---|---|---|---|
| Change From Baseline in Mean Sitting Systolic Blood Pressure (msSBP) at Week 32 | -26.42 ± 0.566 | -25.75 ± 0.781 | -24.32 ± 0.816 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Aliskiren + Amlodipine | — | 14/617 (2.3%) | 196/617 (31.8%) |
| Aliskiren | — | 9/315 (2.9%) | 81/315 (25.7%) |
| Amlodipine | — | 9/315 (2.9%) | 104/315 (33%) |
| Event | Aliskiren + Amlodipine | Aliskiren | Amlodipine |
|---|---|---|---|
| Angina pectorisCardiac disorders | 0/617 | 0/315 | 1/315 |
| Atrial fibrillationCardiac disorders | 0/617 | 1/315 | 0/315 |
| Cardiac failureCardiac disorders | 0/617 | 0/315 | 1/315 |
| Hypertensive heart diseaseCardiac disorders | 0/617 | 1/315 | 0/315 |
| Mitral valve incompetenceCardiac disorders | 0/617 | 0/315 | 1/315 |
| Myocardial ischaemiaCardiac disorders | 0/617 | 0/315 | 1/315 |
| Supraventricular tachycardiaCardiac disorders | 0/617 | 1/315 | 0/315 |
| Gastrooesophageal reflux diseaseGastrointestinal disorders | 0/617 | 0/315 | 1/315 |
| Intestinal obstructionGastrointestinal disorders | 0/617 | 0/315 | 1/315 |
| Chest painGeneral disorders | 0/617 | 1/315 | 0/315 |
| Event | Aliskiren + Amlodipine | Aliskiren | Amlodipine |
|---|---|---|---|
| Oedema peripheralGeneral disorders | 131/617 | 53/315 | 76/315 |
| Joint swellingMusculoskeletal and connective tissue disorders | 46/617 | 20/315 | 21/315 |
| HeadacheNervous system disorders | 31/617 | 20/315 | 16/315 |
| Age Continuous(years) | Aliskiren+Amlodipine | Aliskiren Start-Amlodipine Add On | Amlodipine Start-Aliskiren Add On | Total |
|---|---|---|---|---|
| Mean | 58.1 ± 10.81 | 58.4 ± 10.83 | 58.1 ± 10.93 | 58.1 ± 10.84 |
| Sex: Female, Male(Participants) | Aliskiren+Amlodipine | Aliskiren Start-Amlodipine Add On | Amlodipine Start-Aliskiren Add On | Total |
|---|---|---|---|---|
| Female | 305 | 154 | 160 | 619 |
| Male | 315 | 164 | 156 | 635 |
The record gives a start of Nov 2008, a primary completion of Nov 2010 and a completion of Nov 2010. It does not say whether these dates are actual or estimated.
Results were first posted in May 2011, 6 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2011. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Amlodipine · Aliskiren